BG Medicine, which markets a biomarker diagnostic test for heart failure and is developing others, will see its quiet period end on Tuesday, March 15. On February 3, the company raised $35 million by offering 5 million shares at $7, below the original range of $13 to $15. Lazard Capital Markets acted as lead manager on the deal.
